Two factors have been identified as being critical to improving the clinical relevance of DDU testing and APSD measurement: realistic breathing profiles and realistic throat and nasal models.
Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio
01 March 2021, Nottingham, UK: Copley Scientific, the global leaders in inhaler testing equipment, is marking the company’s 75th anniversary with a significant upgrade…
New e-Training service from Copley for pharmaceutical testing
14 January 2021; Nottingham, UK: Copley Scientific is now delivering e-Training, offering customers across the globe remote access to expert tuition on in vitro…
Improving clinical realism: Upgraded IVIVC testing systems from Copley Scientific
29th June 2018; Nottingham, UK: New products from Copley Scientific enhance its offering for improving IVIVCs for orally inhaled and nasal drug products (OINDPs)….
New research demonstrates the ability of the Child Alberta Idealised Throat to deliver better IVIVRs
28 May 2015; Nottingham, UK: New experimental studies using the Child Alberta Idealised Throat (C-AIT) from Copley Scientific confirm that it provides data more…
Copley Scientific introduces improved test set-up for more representative inhaled product testing
5 August 2014; Nottingham, UK: The desire to gain a better understanding of how inhaled products perform in patients has highlighted the importance and…
Introducing the new Alberta Idealized Throats from Copley Scientific – closer IVIVC in inhaled product testing
1 December 2010; Nottingham, UK: The Alberta Idealized Throat is a new product from Copley Scientific designed to improve in vivo/in vitro correlation (IVIVC)…
Demonstrating Bioequivalence of Orally Inhaled Products Safe and cost-effective treatments for respiratory diseases are facing a growing demand. The demonstration of bioequivalence within locally…
